TABLE 3

Recommended Meningococcal Vaccines by Age Group

Age GroupVaccineRoutine RecommendationDosing Schedule
2 mo to 10 yMCV4-D (Menactra, Sanofi)aHigh-risk onlyaPrimary
High-risk onlyb• Age 9 to 23 mo: 2-dose series with 12 weeks between doses
High-risk onlyc• Age 2 to 10 y: 1 dose
Booster (for persons who remain at risk)
• First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y
• Every 5 y for children who received primary series after 7th birthday
MCV4-CRM (Menveo, Novartis)Primary
• Age 2 to 6 mo: 4 doses at 2, 4, 6, and 12 mo
• Age 7 to 23 mo: 2 doses should be given, with the 2nd dose given in the 2nd year of life
• Age 2 to 10 y: 1 dose
Booster (for persons who remain at risk)
• First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y
• Every 5 y for children who received primary series after 7th birthday
HibMenCY-TT (MenHibrix, GSK)Primary
• Age 2 to 18 mo: 4-dose series with doses at 2, 4, 6, and 12 to 15 mo
Booster (for persons who remain at risk)
• Use MCV4-D or MCV4-CRM (see above)
11 to 21 yMCV4-ACWY-D (Menactra, Sanofi)Healthy and high-riskPrimary: healthy
• Age 11 to 15 y: 1-dose primary series with booster at 16 to 21 y
• Age 16 to 21 y: 1 dose, no booster necessary
Booster: healthy
• Age 16 to 21 y: 1 dose
Primary: high risk
• 2-dose primary series for those who have asplenia, HIV infection, or persistent compliment component deficiency
Booster (for persons who remain at risk)
• First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y
• Every 5 y for children who received primary series after 7th birthday
MCV4-ACWY-CRM (Menveo, Novartis)Healthy and high riskPrimary: healthy
• Age 11 to 15 y: 1-dose primary series with booster at 16 to 21 y
• Age 16 to 21 y: 1 dose, no booster necessary
Booster: healthy
• Age 16 to 21 y: 1 dose
Primary: high risk
• 2-dose primary series for those who have asplenia, HIV infection, or persistent compliment component deficiency
Booster (for persons who remain at risk)
• First booster 3 y after primary series for children who received primary series before age <7 y, then every 5 y
• Every 5 y for children who received primary series after 7th birthday
HibMenCY-TT (MenHibrix, GlaxoSmithKline)Not approved for this age group
  • a For children who have complement component deficiency or functional or anatomic asplenia or who are part of a community or organizational outbreak or who are traveling internationally to a region with hyperendemic or endemic meningococcal disease. For infants receiving the vaccine before travel, the 2 doses may be administered as early as 8 weeks apart. Infants who have functional or anatomic asplenia should wait until 2 years of age to prevent immune interference with PCV13.

  • b For children who have complement component deficiency or functional or anatomic asplenia, or who are part of a community or organizational outbreak or who are traveling internationally to a region with hyperendemic or endemic meningococcal disease.

  • c For children who have complement component deficiency or functional or anatomic asplenia, or who are part of a community or organizational outbreak. Hib-MenCY-TT is not recommended for use in children who are traveling internationally to a region with hyperendemic or endemic meningococcal disease. MCV4 should be used as booster doses for children who are given a primary series with Hib-MenCY-TT.